London UK – 06 June 2019 — GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe,…Original Article
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options
